Publication View

Safety and Immunogenicity of an HIV-1 Recombinant Canarypox Vaccine in Newborns and Infants of HIV-1-Infected Women (2005)

Johnson,
D.C.,
McFarland,
E.J.,
Muresan,
P.,
Fenton,
T.,
McNamara,
J.,
Read,
J.S.,
Hawkins,
E.,
Bouquin,
P.L.,
Estep,
S.G.,
Tomaras,
G.D.,
Vincent,
C.A.,
Rathore,
M.,
Melvin,
A.J.,
Gurunathan,
S.,
Lambert,
J.

Abstract

Pediatric AIDS Clinical Trials Group protocol 326 is a study of 2 formulations of recombinant canarypox ALVAC vaccine (vCP205) against human immunodeficiency virus type 1 (HIV-1). HIV-1-exposed infants were randomized to receive 1 of 2 formulations of vCP205 or placebo at birth and 4, 8, and 12 weeks. The vaccines were safe. Lymphoproliferative responses were detected at >/=2 time points in 44%-56% of vaccinees and none of the placebo recipients. A cytotoxic T lymphocyte response on at least 1 occasion was detected in 62.5% of infants in cohort 1 (10(6.08) median tissue culture dose [TCID(50)] vaccine formulation) and 44% of infants in cohort 2 (10(6.33) TCID(50) vaccine formulation). Rare mucosal immunoglobulin A responses and no measurable vaccine-elicited serum antibodies were detected. In children, vCP205 appeared to be safe and immunogenic

Publication details

Download	http://www.ucl.ac.uk/research/publications/?action=search&pubid=106991
Repository	UCL Research Publications Index (MyOPIA) (United Kingdom)
Keywords	1, 12, 2, 4, 8, A, AIDS, AND, Antibodies, Antibody, ARTICLE, birth, CHILDREN, CLINICAL, clinical trial, Clinical Trials, CLINICAL-TRIAL, COHORT, CULTURE, HIV-1, Human, HUMAN IMMUNODEFICIENCY VIRUS, HUMAN-IMMUNODEFICIENCY-VIRUS, immunodeficiencies, immunodeficiency, immunoglobulin, INFANT, INFANTS, IS, JOURNAL, LYMPHOCYTE, NEWBORN, NO, OF, pediatric, randomized, RECIPIENTS, RESPONSES, SAFETY, serum, THE, TIME, TISSUE, Tissue Culture, TRIAL, TRIALS, unit, VACCINE, Vaccines, VIRUS, WOMEN
Type	JOUR
Relation	2129-2133